Cytosar
(Cytarabine)ApprovedSmall molecule
TevaCytarabine is a chemotherapy drug used to treat certain types of blood cancers like leukemia and lymphoma by stopping cancer cells from growing and dividing.[2] Cytosar is currently approved and in use across 92 indications[4].[1]
Cytosar is one of 1093 small molecule programs targeting T-cell acute lymphoblastic leukemia. It is currently in Approved.
92
Indications
938
Total Trials
27
Active Trials
1,092
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 92 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Cytosar
TevaApproved
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Acupan
YYonsei University
Preclinical
Paracetamol
GSKPreclinical
Rilvegostomig
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q4 2026
Phase 3Active, not recruiting
Acute Lymphoblastic Leukemia
NCT02883049
Phase 1/2Active, not recruiting
T-Cell Acute Lymphoblastic Leukemia
NCT03808610
Clinical
Trials by Indication[1]
Acute Myeloid Leukemia55 trials
Show 52 more trials
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Completed·—·Phase 1·NCT02070458·30 enrolled
AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy
Unknown status·—·Phase 4·NCT02024308·62 enrolled
Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Not yet recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT06497062·47 enrolled
Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00052299·472 enrolled
Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）
Completed·—·Phase 1/2·NCT01690507·29 enrolled
Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Unknown status·IInstitut de Recherche Clinique sur les Cancers et le Sang·Phase 1·NCT00544999·21 enrolled
Acute Lymphoblastic Leukemia31 trials
Show 28 more trials
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Unknown status·—·Phase 3·NCT00764907·4,000 enrolled
Lymphoma17 trials
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Unknown status·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT03837873·118 enrolled
Show 14 more trials
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Suspended·—·Phase 2·NCT06692452·24 enrolled
Myelodysplastic Syndrome7 trials
Show 4 more trials
Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00077116·31 enrolled
Leukemia7 trials
Show 4 more trials
48 more indications
Mantle Cell Lymphoma7 trials
Show 4 more trials
Acute Leukemia6 trials
Bone Marrow Transplantation4 trials
Hematologic Malignancies4 trials
Chronic Myelogenous Leukemia4 trials
Chemotherapy4 trials
Myelodysplastic Syndromes3 trials
Induction Chemotherapy3 trials
Newly Diagnosed3 trials
Chidamide2 trials
Lymphoid Malignancies2 trials
T-cell acute lymphoblastic leukemia2 trials
Relapsed/Refractory AML2 trials
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
Terminated·—·Phase 1·NCT03735446·2 enrolled
Diffuse Large B-Cell Lymphoma2 trials
Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma
Withdrawn·—·Phase 2·NCT03719560
Treatment2 trials
MDS1 trial
Adoptive Transfer of Haplo-identical DLI for AML and MDS
Completed·—·Phase 1/2·NCT02046122·19 enrolled
Lymphoblastic Lymphoma1 trial
Anaplastic Large Cell Lymphoma1 trial
Efficacy and Safety1 trial
Maintenance Therapy1 trial
Advanced Hematologic Malignancies1 trial
Elderly Patients1 trial
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06744556·60 enrolled
Relapse1 trial
BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL
Terminated·—·Phase 3·NCT02366663·3 enrolled
Anemia1 trial
Treatment of Sickle Cell Anemia With Stem Cell Transplant
Terminated·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·N/A·NCT01350232·2 enrolled
ART1 trial
Myeloid Neoplasm1 trial
Hematopoietic Stem Cell Mobilization1 trial
Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies
Unknown status·—·N/A·NCT05510089·62 enrolled
Relapsed/Refractory1 trial
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL
Completed·—·Phase 1·NCT03349281·6 enrolled
Neutropenia1 trial
Refractory AML1 trial
CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML
Unknown status·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 3·NCT03384225·120 enrolled
B-cell non-Hodgkins lymphoma1 trial
Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
Completed·—·Phase 2·NCT00577629·39 enrolled
Adult Acute Lymphoblastic Leukemia1 trial
Carboplatin1 trial
Hematological Malignancies1 trial
Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
Recruiting·—·N/A·NCT05536154·68 enrolled
Induction Therapy1 trial
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
Recruiting·—·Phase 2·NCT06221683·500 enrolled
Stem Cell Transplant1 trial
Safety and Efficacy1 trial
Regulatory
FDA Approval Timeline[5]
Dec 21, 1987
CYTARABINE
NDA NDA016793
Apr 1, 1999
DEPOCYT
NDA NDA021041
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Cytosar drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Cytarabine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]